Drug intelligence / Profile preview

UIC201604

Development stage: Unknown
Lead developer: Korea United Pharm

Overview

UIC201604 is an investigational drug developed by Korea United Pharm. Its precise mechanism of action, molecular modality, and therapeutic class have not been disclosed in public sources. The compound has been studied in early-phase clinical trials, specifically for its safety and pharmacokinetics when co-administered with another investigational agent, UIC201603, in healthy volunteers. There are no approved indications or known adverse events reported for this drug as of the latest available data[1][2][3][4].

Beyond the preview

Go deeper on UIC201604.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UIC201604.

Explore the full profile